



Infectious Complications in Solid Organ Transplant Recipients

This program is an overview of the pathophysiology, diagnosis, and treatment of infectious complications of solid organ transplant.

Educational Objectives

At the conclusion of the program, participants will be able to:

- Recognize risk factors that may predispose transplant recipients to the development of CMV, BKV and invasive fungal infections
- Compare and contrast the available approaches for prevention of CMV disease
- Discuss the role of immunosuppression modification in the management of infectious complications in the posttransplant setting
- Be able to identify the potential pharmacokinetic and pharmacodynamic drug interactions that may arise with the treatment of various infectious complications

Accreditation



TG Medical Education, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing education and complies with the Criteria for continuing pharmacy education programming. This program provides 1.0 hour (0.1 CEU) of continuing pharmacy education credit (ACPE Universal Program Number 454-999-06-003-H01). The original program release date is April 3, 2007.

Statement of Credit

Following the successful completion of this course and post-test, participants will receive their Statement of Credit, which is available for printing. TG Medical Education does not mail Statements of Credit for its online content. Prior to completing the online program, please make sure that your computer is hooked-up to a working printer.

Intended Audience

This educational activity is intended for pharmacists who care for patients who receive solid organ transplants.

Support

This program is supported by an educational grant from Roche Pharmaceuticals. There is no fee for this program.

Program Faculty

- **Faculty Disclosure Statement** In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, TG Medical Education requires that faculty members disclose any relationship (e.g., shareholder, recipient of research grant, consultant, or member of an advisory committee) that the faculty may have with commercial companies whose products or services may be mentioned in their presentations. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on faculty presentations.
- **Faculty and Disclosure Information** Christin Rogers, PharmD, BCPS—Clinical Pharmacy Coordinator, Solid Organ Transplant, Beth Israel Deaconess Medical Center, Boston, MA.
 - Speaker with Honorarium
 - Astellas Pharma US
 - Does not plan to discuss unlabeled/investigational uses of a commercial product.